Thank you. Thank you everybody for joining. My name is Michael Leuchten, I am one of the pharma analysts here at Jefferies. Day two of the conference, hope you are enjoying it. It is my distinct pleasure to have UCB with us now. We have the CEO, Jean-Christophe Tellier. Thank you.
Yeah.
We will do a fireside chat. I will try to go through UCB next chapter, BIMZELX, neurology, see where we can go in 25 minutes. So maybe to start with
The answer needs to be short.
Yeah. Well
Which is a challenge for me anyway.
Okay
I will do my best.
My first question is, in your view, has UCB moved away from being a company with concentration risk of having one strong growth driver to having more of a balanced portfolio?
Well, I think it's important. First of all, I think in our industry, having one big growth driver that concentrate sales, it's not something which is unusual, and it's not necessarily a bad thing, actually. I do feel that having one big product that constantly can push the revenues to new limits is important. The role and the objective would be, of course, to try to push this at the maximum. When sometimes people ask me, "Are you afraid to get one big blockbuster that creates big revenue and potential big risk of a patent cliff?" I say, "I love big patent cliff." Because big patent cliff means that we have big revenues before, and so we can invest, we can do something with it. That's one piece.
But as you said, the advantage of our current situation is not only we have a good anchor of our growth for the next 10 years or plus, because BIMZELX patent will be lost in 2037. We have on top of that, four additional growth drivers that have also patent in the early 2030s. So, in a nutshell, we are currently, and for the last two years, we have been starting to progress on this new growth agenda.
Yeah. And I guess, I think it's actually fairly impressive. BIMZELX is a big growth driver now, but it's not the first time UCB has done it. So, you are kind of a repeat offender in that sense. So, that's impressive. But if you look at the next growth phase, you also have done BD. You've done interesting acquisitions. So when you now look at the sort of next wave, and BIMZELX LOE is a long way out, how much of that growth do you think is already within UCB, and you now try to find exactly where to place those assets, and how much do you think BD is still going to be part of it?
Well, I think there are two elements in your question. The first one is, how strong do you feel yet we need to be in order to provide growth for the next 10, 15, and the decade after? And of course, it depends on the probability of success of the different assets, right? So, you can build a good portfolio, and if you have a good hypothesis, and then you translate that into meaningful transformation for the patient, then you get the growth for the decade after the next decade. But we need also to manage a portfolio, and then I don't think that anyone can increase the likelihood of success on the long term without inorganic growth. And building and strengthening the pillar that you have internally with external addition, seems to me a very good strategy in order to increase the likelihood of success.
If the question is, with what you have in your hands today, do you feel that you are comfortable to grow after 2035 for the next decade? I will tell you, if everything that we have in our hands currently works, yes. But then, it's binary, right? I mean, the assets could be good or negative or positive. Strengthening the numbers of bets that you have, in order to increase the likelihood of success, I think it's the right thing to do. How to do that? In our case, we always have concentrated and focused on two things. One, create opportunity in inorganic growth in areas we know already quite well, in order to increase probability of success. It's not new therapeutic areas, it's areas where we know quite well the pathology, the patient's population, and the biology.
Which means that when we do our due diligence, we are likely to have a higher percentage of success than otherwise. Two, it's what is the best complement to what we have? What is the next phase? What is the next environment, pathway, platform, biology that can complement what we have and strengthen the offering that we have for a broader patient's population? This is what we are doing in immuno-inflammation. If you think about moving from BIMZELX, an anti-IL-17A/F, to bispecifics such as galvokimig, through T-cell engagers, you can see the evolution of the mindset of trying to get better, deeper, longer ability to resolve autoimmune disease by creating an immune reset and providing a unique outcome for the patient. Neurology is a little bit different for us, because neurology, we had two pillars, basically. We have one which was epilepsy, and another one which was neurodegeneration.
In epilepsy, we have moved from symptomatic treatment to try to get closer to disease modification of very debilitating rare disease with epilepsy. We did that with the acquisitions of Zogenix and FINTEPLA, and we have now that also with Neurona and cell therapy for very severe temporal lobe epilepsy. You can see that in this case, we are moving towards being more specific, but still in the area of expertise, even though cell therapy is quite new for us. You can see when you look at all of that together, a good balance between the two therapeutic areas. Two, a good balance of risk versus new platform, new targets, or something that we know already quite well, and an ability to complement what we have internally.
Very clear and helpful. Thank you. Maybe before we go into BIMZELX a little bit more, when you sort of look at what the sell side writes, the questions that you get in meetings, like at conferences like these, what do you think is still most misunderstood by investors about UCB?
It's a difficult question. I was hoping not to have this question, actually.
Sorry.
No, it's fine. You may not like the answer. I mean, not you, but people in the room. It's difficult to well understand the potential of companies, so I can understand that. If I look at my 10 years of CEO up to now, questions always have been around, "How do you think you will be successful?" Then when we manage to go to the next step, the question has always been, "Okay, that's how I understand, but what about the next step?" Right? It's always like if you have not demonstrated enough.
Despite 10 years of execution, successful management of VIMPAT, CIMZIA, launch of BIMZELX, the four clinical trials where we have superiority, the good result that we have today, it seemed that it's still not enough to convince and to create an environment of trust and confidence in the future, which is important because this is why we are here in a sense. We are here not to just explain what we have done, but we are here mainly to give you and to give the investors a story to believe and an ability that, despite the level of a stock now, it's still a good moment to invest. It's still a good moment to invest for at least few reason.
One, we have an actual ability to deliver result that have been demonstrated year after year, and that should give a certain level of confidence that it will continue. Two, we have been able to demonstrate that having an innovative scientific hypothesis can be translated into differentiated medicine for the future. That should give also confidence that we can do it again for the next generation of innovation. Three, we are able to manage the P&L in such a disciplined way that we have the space to do some strategic move and to integrate inorganic growth into organic growth way ahead. Because if you look at the industry so far, there is not so many companies with 10 years of growth, with the balance sheet that we have, with already have done four acquisition this year, and with this ability to continue to develop growth.
Evaluation of the pipeline, confidence about what we have already delivered, give the chance to believe into what will come in the future. I think these are the point that are important in the evaluation.
Thank you. Very clear. Maybe let's spend a bit of time on BIMZELX. You've taken the peak sales to above EUR 7 billion
Yeah
expectation. Can you talk about the biggest change within your thinking? Is it size of the eligible patient populations? Is it penetration rates of biologics more broadly in the market? Is it competitiveness of BIMZELX within the market? Competitive environment maybe not shaping up?
No, it's a great question. I mean, if I need to select one element for BIMZELX in terms of potential in the future, I would really focus on the differentiation. It looks like a crowded market, which it is. It looks like the products are well established in this market, and so competition is quite difficult. But to me, at the end, it's a very simple question to solve. What are the facts, and what are the decision that you need to take based on these facts? I would summarize it in a very simple way. We have been able, with BIMZELX, to demonstrate superiority versus standard of care with four different competitors in two different indications, psoriasis and psoriatic arthritis. It's unprecedented. Nobody have done that before.
Now, because nobody had done that before, the way the market reacts in terms of preference, in terms of scientific guidelines, in terms of recommendation, is not exactly following what I feel would be the normal consequences of proving and delivering this data, right? If it was you, if it was someone from your family that suffers from psoriasis today or psoriatic arthritis, what would you expect your physicians to do? Do you expect your physician to say, "Look, there is a good product. I know it quite well, and if it doesn't work, I will give you the best one after." Why don't do the opposite? A logical sequence would be to start with the highest likelihood of success, and if it doesn't work, then you can try something else.
From a purely rational data fact-based, in this indication when we have demonstrated superiority, we should be guided by the scientific community, by the key opinion leaders, by all of the scientific society to say, "You should start by the most efficient product." It's not the case because it has not been the usage, because also the data was not there before. So it takes a little bit of time to get to this habit, and the system sometimes doesn't help. PBMs, rebates, and ability to secure certain position and step edit are not based on superiority, but based on the rebate and the financial interest of the PBM. So there are misalignment of incentive, there are practice, there are usage, so it takes time. But I'm very confident we will be there just because now we have 150,000 patients with a very strong experience.
In our head-to-head versus SKYRIZI in PsA, we have the safety profile than SKYRIZI. We have the reputation to be very easy and very safe. So basically, I think all of the indicators are on the green for us to achieve the at least EUR 7 billion. And for the one we have in mind, why just seven? Are you conservative? The Jesuit answer to that is we said at least seven, so there is no upside limit, so you can build the limit that you want.
Got it. Can I just check, the comment is, does that apply across all indications? So is it HS, PsA, PSO?
I do think it's applying to all indications. First of all, our superiority is in psoriasis, so there is no reason in psoriasis we will not be able to deliver. Two, on psoriatic arthritis, we have a superiority. On top of that, psoriatic arthritis is 30% of the patients suffering from psoriasis. Leading in psoriasis and having superiority in psoriatic arthritis should lead us to be on the first positions in these two indications. Then you have HS. HS, we are by far the product with the highest numbers of data and with the most compelling set of data. HS is a beginning. I mean, we are just in the beginning of the story here. It's a very complex disease. It's a disease which is not easy to treat, and we all know that.
There is probably multiple factors that lead to the clinical explanation and clinical expression of the disease. There is on average seven years between diagnostic and symptoms, so we need to accelerate that. We need to treat patients earlier, and my hope is that we will have in HS the same thing that we had in RA for those of you who are from my age in the room, which means that at the beginning of TNF-alpha, we still had some patients suffering from RA with huge damage disease on their joints. It doesn't exist anymore. Hopefully, in 10 years from now, there will be no patient with HS suffering from abscesses or tunnels because we will be able to treat the patients earlier. Our data are compelling.
The market is growing in HS, no question there, and I think we will be able to lead there with what we have.
Got it. I think just as a comment from me, I think it's fair to reiterate that the way you did the HS studies, that was the highest bar one could set itself. As competitive data comes out with the antibiotics use, you set yourself a very high bar, and you hit it where others have been.
Well, thank you for that. You give me opportunity maybe, sorry, you didn't ask the question, but to give you four elements that I would like you to think and to see when you will look at the data of any compound in HS. First, is it a comparison versus standard of care or not? Two, on what criteria of efficacy it is evaluated? Three, what is the patient's population in terms of severity? Four, how much placebo effect you have? Five, how the antibiotic treatment is considered in the clinical trial? You need to get all of these components in order to try to think about what this percentage of efficacy give compared to others.
Understood. Then maybe last question on this. I think the biologic penetration rate in rheumatoid arthritis is about 50% now, give or take. It is much lower in dermatological settings. Do you think we'll get to 50%?
Yeah, I do feel that dermatologists get more and more used to usage of biologics than before. Psoriasis have helped a lot actually, when you look at the percentage now of dermatologists comfortable in using biologics. However, I think it is fair to say that it will never be all dermatologists. I mean, there are dermatologists who want to prefer to get different type of patients' populations and different allocations of their time. Actually, it's also even more true for HS, because HS patients are complex, diagnostic is not easy to do, treatment is not easy to implement. So the percentage of dermatologists who will be active and really engaged into HS and in psoriatic, and so in biologics, is a little bit different. However, for psoriatic arthritis, we see already a large populations of dermatologists who are active in psoriasis, who are currently treating psoriatic arthritis.
It's quite logical, because basically you suffer from psoriasis and suddenly you have a pain on your joint. Well, you will see your dermatologist and you will, during the conversation, you will say, "Look, my skin is doing like that, but however, I have start to get some pain somewhere on my back, on my knee, on my hands, and so what it is?" As long as it is not very severe, dermatologists are highly tempted to say, "No worry, I will take care of that." The questions to me is, how much a better control of psoriasis will have an impact potentially on the severity of psoriatic arthritis, and how many patients will go directly to the rheumatologist versus the one that will come to the rheumatologist after a long period of treatment at the dermatologist level?
This is where maybe these patients may have a delay before getting access to the right treatment, because the dermatologist maybe keep the patient, but not really with the best possible treatment.
Understood. Maybe a few minutes on neurology, if you move on from BIMZELX. So you've got RYSTIGGO, you've got ZILBRYSQ, [inaudible] franchise. Talk a little bit about differentiation here. This is a market that's becoming increasingly competitive as well.
Yes. Well, initially we thought that myasthenia gravis was something close to a rare disease. Actually, it's everything but a rare disease in a sense. The numbers of patients are bigger than what was described few years ago, and the level of the competition is really very high. So, it's more a specialty type of business than a rare disease. On top of that, there are two things that are important to consider for myasthenia gravis. The first one is, I was mentioning a certain level of frustration for guidelines in psoriasis or immuno-inflammation. It's even less the case in myasthenia gravis. I mean, there is a huge diversity of habits from a prescription standpoint. Some physicians continue to do IVIG very often, immunosuppressors sometimes.
The penetration of the new categories such as anti-FcRn or anti-C5 are not really the same at different part of the geography, and sometimes even in the same hospital. I mean, I've been myself exposed into that recently. So first of all, there is a huge diversity of patient and symptom, and then there is a huge difference in terms of habit of the physician. On top of that, you add a layer of a lot of different competitors that are coming in and continue to come in. So what do we have? We are the only companies, we have one anti-FcRn and one anti-C5, which give us the sense to better adjust what is the best for the patients, and we don't push one against the other, because it doesn't make really sense.
Two, for each of the product, we have a very specific profile that for certain patients and for certain physicians are very useful. Three, don't forget that when you think about the future with potential T-cell engagers, and in particular BCMA x CD3 target, these are mainly patients with a high level of IgG, which is by nature what an anti-FcRn do. So if you think about the future portfolio, adding to what we have, the future and the next generation of potential treatment for this patient, I think will be very helpful for us.
Yeah. Okay. I was going to go there next in the last five minutes, is sort of the BD choices that you've made. It's pretty obvious that you've gone from symptom control to more of modifying a disease biology.
Yeah.
I think that seems to apply across the therapeutic areas that you operate in.
Yeah.
Can you talk a little bit about Neurona and Candid in a construct?
Yeah. So maybe a little bit of a context here. You need to consider UCB today, as I said, as a moment where we are executing on five growth drivers and multiple indication. It was not the moment for us in 2026, and it will be unlikely in 2027, for us to concentrate or to add into our portfolio a new late-stage product, right? Because we were occupied to execute and successfully execute the launches. However, as I said, strengthening the early portfolio and adding into our modalities, different modalities in the areas we want to build and develop expertise was, of course, very important for us. So that's the reason of the choices of IMIDomics, Antengene, Neurona, and Candid.
It fits more or less exactly with this profile where we are not adding a potential execution strong need for the next couple of years, but we are more expanding and adding our capabilities and expertise in the areas we are already present. All of them have an, is and are in illustrations of that. So if you take Neurona, for example, as I mentioned, cell therapy in very severe epilepsy, where basically you take the patient just before surgery, and for some of them, they cannot even get access to surgery because there is a bilateral damages that you cannot solve through surgery. So it will be for them an ability to move from a state where they cannot socialize. I mean, these kids basically sometimes they have more than 40 seizures, so they are really very invalid at home in a sense.
It's also, of course, a huge impact for the entire family. So the objective here is to provide a treatment by injecting cells into the brain, then suddenly we can help them to recover and to diminish the seizure, and so to develop cognitive functions and to develop brain development in a much better way. That's exactly what we're trying to do. We have started with FINTEPLA and Dravet, and we have also, in a way, doing that with Antengene and Candid. So in both, it's trying to get closer to the physiopathology of the disease, try to better understand and address the need of the patient, and at the same time, doing that in such a way that we aim to give a long-term benefit. In immuno-inflammations, getting closer to immune reset is an ability to say, "Look, in autoimmune disease, the systems is damaged.
How to recreate a balance in the system in order to get a normal answer?" You really need to think about the immune system as an equilibrium between stimulations and reaction. You have a virus that come in, and then you stimulate the defense, and then you recreate the balance, is the principle of vaccine in a sense. T-cell engager is something like that. You better connect B cells and T cells in order to create an answer that potentially rebalance the immune system and being able to create a new equilibrium where there is much less autoimmune activities. Autoimmune disease is nothing else that our own immune system which doesn't recognize ourself. So if you shift this ability and translate this negative signal into a new neutral signal, you can treat a lot of different disease together.
It is getting away from a specific target to a more system balance and new equilibrium.
Yeah, very clear.
Sorry, I am very fast in the answer because I have the timing just in front of me.
Very disciplined. Okay, last question then, and maybe this is more for your CFO, Sandrine, who is in the front row.
No comment.
Okay. If BIMZELX continues to do what it does, obviously there is some investment that is required, but you've got the EVENITY benefit as well. UCB is going to continue to generate a lot of cash flow. Can you talk about priority of capital allocation in, no pressure, 30 seconds?
I mean, no, it's a very good question, and I speak under the control of Sandrine. What we need to do is three things. One, we need to make sure that we continue to focus where we think we can make a very important difference. Our objective is not to cover everything and not to invest in everything, but more to try to focus on areas where we think we have a chance to see things differently, and we can translate scientific hypothesis into a real benefit for the patients. Two, we need to make sure that we do that in order with a good balance of our capital allocations and access. For example, we have decided to invest into a manufacturing site, a mammalian manufacturing in the U.S. because we are not present there.
Strategically, it doesn't make any sense not to be present there. The regionalizations of the manufacturing, the double sourcing in order to minimize the risk, making sure that we can provide to the patient the security of the supply that they deserve. Three, we need to make sure that, moving forward, we are increasingly investing into potential area when we think we have a chance to success. Up to now, it was very early stage in areas we think we know quite well. Probably moving forward, and it will depend on the result of our internal pipeline, we'll potentially add in external acquisitions also in organic. What I would like you to think and keep in mind is that the uniqueness of our position, it's because we are not under the pressure of time.
We can do that to find the best solution when we find it, not because we have to do it because we have no other choice. We have the choice. Choice is not always easy to do, but it's a luxury that not everyone have.
Sure goes after you. Thank you very much.
Thank you.